Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Fernando Calero Baquerizo

Internal Medicine Providence, RI Medical Doctor

NPI 1407197395 CMS profile 1368854

78 Baker St, Providence, RI 02905

Open in the dashboard

General payments

$1,476

107 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Fernando Calero Baquerizo of Providence, RI is reported in the CMS Open Payments database as having received $1,476 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $15 1
2022 General $50 2
2021 General $87 4
2020 General $435 33
2019 General $890 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fernando Calero Baquerizo
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Fernando Calero Baquerizo were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Fernando Calero Baquerizo Internal Medicine median Middle half National median
2019 $890 $159 $48–$570 $163
2020 $435 $119 $33–$402 $114
2021 $87 $135 $37–$521 $132
2022 $50 $141 $42–$496 $149
2023 $15 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Sanofi-Aventis U.S. LLC $245 21 payments
  2. Novo Nordisk Inc $157 11 payments
  3. GlaxoSmithKline, LLC. $142 12 payments
  4. AbbVie, Inc. $130 6 payments
  5. AstraZeneca Pharmaceuticals LP $116 9 payments
  6. Amgen Inc. $114 7 payments
  7. Astellas Pharma US Inc $73 5 payments
  8. Pfizer Inc. $71 5 payments
  9. Allergan Inc. $67 4 payments
  10. Amarin Pharma Inc. $51 3 payments
  11. Other $309 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,476 107 payments
Products named General payments · program years 2019–2023
  1. TRELEGY ELLIPTA $142 12 payments
  2. Prolia $114 7 payments
  3. SOLIQUA 100/33 $113 11 payments
  4. QULIPTA $112 5 payments
  5. TOUJEO $97 6 payments
  6. Ozempic $90 6 payments
  7. MYRBETRIQ $73 5 payments
  8. EVENITY $72 4 payments
  9. FARXIGA $68 5 payments
  10. SYMBICORT $48 4 payments
  11. Other $871 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

5,819

Median for Internal Medicine: 777

Drug cost

$1,417,180

Median for Internal Medicine: $73,373

Branded share of claims

20.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 133 $552,523
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 84 $331,182
Jardiance Empagliflozin Brand 91 $74,799
Eliquis Apixaban Brand 81 $67,009
Trulicity Dulaglutide Brand 55 $61,592
Darunavir Generic 61 $53,460
Descovy Emtricitabine/Tenofov Alafenam Brand 21 $51,445
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 12 $41,031
Ozempic Semaglutide Brand 29 $26,068
Isentress Raltegravir Potassium Brand 11 $25,467

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$14,939

Of which drugs: $11

Medicare patients

145

Average age 74

Services billed

323

37 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 37%
Diabetes 26%
Ischemic heart disease 18%
Chronic kidney disease 17%
Depression 17%
Atrial fibrillation 16%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 11 11 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record